The fiscal year 2025 concluded with a dramatic reshaping of the pharmaceutical industry’s top echelons, marked by intense competition at…
Read More
How to tackle the unique pharmacokinetic properties of covalent drugs
Covalent drugs represent a transformative advancement in medicine, offering unprecedented therapeutic efficacy by forming stable, irreversible bonds with their biological…
Read More
US Government Assumes Full Cost of Weight Loss Drugs for Medicare Beneficiaries Through Extended GLP-1 Bridge Program Amidst Insurer Hesitation
The Centers for Medicare & Medicaid Services (CMS) has announced a significant extension of its Medicare GLP-1 Bridge program, shifting…
Read More
Cochrane Review Challenges Clinical Significance of Anti-Amyloid Alzheimer’s Drugs, Pharmaceutical Companies Reaffirm Efficacy
A comprehensive review of 17 clinical trials by the esteemed Cochrane organization has cast doubt on the clinically meaningful benefits…
Read More
Pharma 50: The 50 best-selling drugs of FY2025
The pharmaceutical landscape in Fiscal Year 2025 was defined by a monumental shift at the very apex of the industry’s…
Read More
Genetic Variants Influence Weight Loss and Side Effect Efficacy of GLP-1 Drugs
A large-scale study analyzing the genetic data of 23andMe customers has identified specific variants in two genes that significantly influence…
Read More
How to tackle the unique pharmacokinetic properties of covalent drugs
The landscape of drug discovery and development is witnessing a significant resurgence in covalent inhibitors, a class of therapeutics that…
Read More
Pharma 50: The 50 best-selling drugs of FY2025
The pharmaceutical industry in Fiscal Year 2025 was defined by a dynamic interplay of enduring blockbuster powerhouses and the dramatic…
Read More
How to tackle the unique pharmacokinetic properties of covalent drugs
The landscape of modern medicine has been profoundly shaped by covalent drugs, a class of therapeutics whose impact dates back…
Read More
US Import Tariffs Fail to Deter Biopharma Giants as European Contract Manufacturing Surges for FDA-Approved Drugs
The biopharmaceutical industry is demonstrating a significant and counterintuitive trend in 2025, with companies increasingly channeling investments into European-based contract…
Read More
